-
-
The national epidemic of substance abuse naturally imparts uncertainty and fear in the decision-making process regarding the prescribing of opioids for patients in pain. Statistics alone substantiate the need to validate our decisions with a documented plan of care.
-
Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions.
-
The authors concluded that the use of nonsteroidal anti-inflammatory drugs was associated with an increased risk of coronary events for more than 5 years after the first myocardial infarction.
-
A total of 27,276 U.S. physicians received an invitation to participate in a prospective study using the validated Maslach Burnout Inventory. Of the 26% of physicians who completed the survey, nearly 46% reported at least one symptom associated with professional burnout.
-
Data continue to lend support for the administration of influenza vaccine to individuals with serious egg allergy.
-
Long-term Prevention of Recurrent DVT; Marijuana and the Risk of Schizophrenia; Losartan Improves Erectile Function in Diabetics
-
Stopping smoking before the age of 40 avoids more than 90% of the excess mortality caused by smoking in women.
-
I just had a patient present for consultation, concerned hed transmitted herpes simplex virus (HSV) to two new sexual partners, despite a lack of symptoms or obvious lesions, and expressing concern about the adequacy of suppressive acyclovir therapy. He had tried to convince both new partners it was not him! I had to disappoint him.
-
A second factor XA inhibitor (novel oral anticoagulant, NOAC), after rivaroxaban, has been approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Apixaban is marketed by Bristol-Myers Squibb and Pfizer as Eliquis.
